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Time Spent at Home Poststroke
“Home-Time” a Meaningful and Robust Outcome
Measure for Stroke Trials
Terence J. Quinn, MRCP; Jesse Dawson, MRCP; Jennifer S. Lees, BA; Tou-Pin Chang;
Matthew R. Walters, MD; Kennedy R. Lees, MD; for the GAIN and VISTA Investigators
Background and Purpose—Stroke outcome assessment requires some measure of functional recovery. Several instruments
are in common use but all have recognized limitations. We examined duration of stay in the patient’s own home over
the first 90 days since stroke—“home-time”—as an alternative outcome likely to show graded response with improved
reliability.
Methods—We examined prospectively collected data from the GAIN International trial using analysis of variance with
Bonferroni contrasts of adjacent modified Rankin scale score categories.
Results—We had full outcome data from 1717 of 1788 patients. Increasing home-time was associated with improved
modified Rankin scale scores (P0.0001). The relationship held across all modified Rankin scale grades except 4 to 5.
Conclusions—Home-time offers a robust, useful, and easily validated outcome measure for stroke, particularly across
better recovery levels. (Stroke. 2008;39:231-233.)
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Accurate assessment of poststroke recovery is essentialfor clinical and trial work. Several tools exist to quantify
functional outcome. Instruments in common use include the
modified Rankin scale (mRS), National Institutes of Health
Stroke Scale (NIHSS), and the Barthel Index (BI).1 Each of
these scales exhibits features that limit their use in clinical
practice. In brief, mRS suffers considerable interobserver
variability,1 BI differentiates disability at extremes of out-
comes poorly,2 and validity of NIHSS as a measure of
functional recovery is questioned.3 Efforts to correct these
limitations have been only partially successful. For example,
using standardized questioning4 reduces but does not abolish
variability of mRS and does so at the expense of increased
complexity and time.
The ideal outcome measure would be simple to understand
and apply with acceptable validity, variability, and respon-
siveness. To date, no stroke outcome measure adequately
meets these criteria. Creation of a novel instrument is unlikely
to achieve immediate widespread acceptance. An alternative
is to derive surrogate outcome measures from routinely
collected patient data. For example, duration of inpatient stay
lends itself to health economic analysis because inpatient
days account for much of the expenditure associated with
stroke.5 Inpatient stay is less valid as a measure of functional
outcome because early mortality and transfer to a long-term
care setting after severe stroke are each associated with
shorter stay.
We hypothesized that duration living independently in the
community could serve as an appropriate outcome measure
less likely to be confounded by survival issues. To explore
this, we measured duration of stay in the patient’s own home
poststroke—“home-time”—from a comprehensive, prospec-
tively gathered stroke outcomes database.
Materials
We extracted and analyzed data from the multicenter, randomized,
controlled trial of the candidate neuroprotectant gavestinel—GAIN
International.6
Resource use data were collected at 90 (7) days. Data were
available for mRS, NIHSS, BI, and duration of hospitalization or
nonhospital placement. Data on placement were from interviews
with the patients or proxies. From the nonhospital placement subset,
we extracted data on length of time spent in own home or relative’s
home—“home-time.” Resource use was censored at 90 days. Where
final follow-up occurred early, last known placement was extrapo-
lated to 90 days. Patients with unknown dates of placement were
excluded from the analysis.
For this preliminary analysis, we used one-way analysis of
variance to assess home-time trends for mRS, NIHSS, and BI
comparing adjacent categories by Bonferroni testing. We used
analysis of variance for subanalysis of home-time by country.
Analyses were performed using StatsDirect statistical software
version 2.4.5 (StatsDirect Ltd, Cheshire, UK).
Received May 11, 2007; final revision received June 6, 2007; accepted June 7, 2007.
From the Gardiner Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK.
Correspondence to Terence J. Quinn, MRCP, Gardiner Institute of Cardiovascular and Medical Sciences, Western Infirmary, Glasgow G116NT, UK.
E-mail Tjq1t@clinmed.gla.ac.uk
© 2007 American Heart Association, Inc.
Stroke is available at http://stroke.ahajournals.org DOI: 10.1161/STROKEAHA.107.493320
231
Results
Full outcome data were available for 1717 of 1788 intent to
treat patients. Data were incomplete for 15 patients and 56
withdrew from the study before 90 days. Mean age was 69.7
(12.2) years, 737 (42.9%) were female, 321 (18.7%) had
intracranial hemorrhages, and mean NIHSS score was 13.1
(6.2).
Mean time in the hospital was 28 days and mean home-
time was 31 days. Home-time was significantly associated
with changes across mRS (P0.0001), NIHSS (P0.0001),
and BI (P0.0001). On analysis of between-category differ-
ences, home-time was significantly associated with change
across all mRS categories except mRS 4 to 5 (Figure).
Analysis of NIHSS and home-time revealed a significant
association with NIHSS categories 0 to 1 (P0.0001), 1 to 2
(P0.0017), 2 to 3 (P0.0013), and 4 to 5 (P0.0001).
Home-time was significantly associated with change
across BI categories 100 to 95 (P0.0001) and 95 to 90
(P0.0001). Change across all other categories of NIHSS
and BI were nonsignificant.
There were significant differences in home-time between
the countries studied (P0.0001). Within all countries, the
relationship between home-time and mRS held.
Discussion
We have shown that home-time has a significant association
with poststroke disability as measured by mRS, particularly
across better recovery levels. Although intuitive, this relation-
ship has not been demonstrated previously. mRS is the
preferred outcome measure in acute stroke trials7 and, as
such, our findings provide strong evidence of the validity of
home-time as a potential outcome measure.
Home-time has potential advantages over mRS in applica-
tion and interpretation. Interobserver variability limits use of
mRS.1 An objective measure such as home-time should give
near-perfect reliability and would not require formal training.
The continuous nature of home-time lends itself to more
powerful statistical techniques than traditional dichotomized
or ordinal outcome measures.8 Home-time is generalizable
and could be applied to any potentially disabling condition.
A further strength of home-time is its immediacy. Discus-
sion of possible treatment benefit is essential for informed
consent. The abstract outcome measures used in trials make
this already challenging task more difficult. Home-time offers
an outcome measure that should be easily understood by the
lay public and other medical professionals.
Association of home-time with NIHSS and BI was less
convincing. We do not interpret this as a failing of home-
time; rather, home-time accentuates the limitations of NIHSS
and BI. “Floor and ceiling” effects of the BI are well
recognized.2 NIHSS measures physical impairment, not tak-
ing into account the ability to compensate for functional
deficit; thus, it is likely to be responsive to change at extremes
of outcome only. Home-time change across grades was
significant only at the lower end of these scales.
Patients in the GAIN study were broadly representative of
a clinical trial population. However, all patients in GAIN
were independent at baseline. Home-time may be less valid as
an outcome measure if applied to a more disabled population
such as seen in routine clinical practice; however, for trials,
premorbid residence at home could be an objective entry
criterion.
Rehabilitation is often necessary poststroke, reducing
short-term home-time to achieve longer-term improved out-
comes. As such, a 90-day cutoff is most appropriate for
home-time analysis. It is unlikely that meaningful inpatient
rehabilitation will continue past 90 days. Ninety-day outcome
assessment has become standard in clinical trials and so
ascertainment of home-time would not necessitate changes to
study protocols.
We do not claim home-time to be the perfect measure of
outcome; it is prone to many of the same limitations as other
accepted outcome scales. By measuring home-time at specific
cutoffs, data may be biased by “early” and “late” responders,
ie, those patients whose recovery time from disabling stroke
is substantially longer or shorter than average. Although
important at the individual patient level, such influences are
less important in the context of large multicenter trials and it
is in this area that we propose the use of the home-time
instrument.
We assume that increasing home-time is a positive out-
come because return home is desired by patients and will
reduce total costs. Home-time makes no measure of level of
care required to facilitate discharge; a large package of care
may allow return home but at substantial economic expense.
Potential for provision of care by state or family will vary
between centers in an international trial. Subanalysis con-
firms the expected differences in home-time among countries.
Although a potential limitation, the influence of country and
culture is not unique to home-time; significant differences
across countries are also seen for mRS, NIHSS, and BI in the
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Figure. Forest plot of mean 90-day home-time 95 CIs ver-
sus mRS. N1717 (of which mRS 0197; mRS 1268; mRS
2205; mRS 3214; mRS 4366; mRS 5143; mRS 6
(death)324. P0.0001 comparing adjacent categories
except mRS 4 to 5 (P0.37) and mRS 5 to 6 (P0.0003).
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GAIN data set.6 The persistence of differences in home-time
between mRS categories, even in those countries with high or
low average home-times, offers some reassurance of its
validity as an outcome measure. Other factors external to the
patient such as marital status, dependents, and healthcare
insurance may influence home-time, but such data are not
routinely collected and so appropriate analysis could not be
performed.
Despite its plausibility, we recognize that the potential use
of home-time needs to be confirmed. We have derived
home-time retrospectively from previous trial data and thus
can make no assessment of its use in real-time clinical
practice. However, GAIN was a typical, multicenter, intention-
to-treat trial and, as such, we assume that our findings would
hold for future trials. Rather than replace established instru-
ments, home-time could complement other trial end points.
Integration with other scales could generate a powerful global
outcome statistic.9 It would be of interest to examine home-
time in existing trial data sets of thrombolysis or hemostasis.
In summary, home-time assessment offers robust, objec-
tive, easily communicated information on stroke outcomes.
We encourage trialists to measure home-time and consider its
inclusion as a clinical end point.
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